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The dopaminergic (DAergic) nigrostriatal tract has an intrinsic regenerative capacity
which can be impaired in Parkinson’s disease (PD). Alpha-synuclein (aSyn) is a major
pathogenic component in PD but its impact on DAergic axonal regeneration is largely
unknown. In this study, we expressed pathogenic variants of human aSyn by means
of recombinant adeno-associated viral vectors in experimental paradigms of DAergic
regeneration. In a scratch lesion model in vitro, both aSyn(A30P) and aSyn(A53T)
significantly reduced DAergic neurite regeneration and induced loss of TH-immunopositive
cells while aSyn(WT) showed only minor cellular neurotoxic effects. The striatal density of
TH-immunopositive axons in the striatal 6-OHDA lesion mouse model was attenuated only
by aSyn(A30P). However, striatal expression levels of the regeneration marker GAP-43 in
TH-immunopositive fibers were reduced by both aSyn(A30P) and aSyn(A53T), but not by
aSyn(WT), which was associated with an activation of the ROCK signaling pathway. Nigral
DAergic cell loss was only mildly enhanced by additional overexpression of aSyn variants.
Our findings indicate that mutations of aSyn have a strong impact on the regenerative
capacity of DAergic neurons, which may contribute to their pathogenic effects.
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INTRODUCTION
Since worldwide life expectancy increases, the numbers of indi-
viduals with Parkinson’s disease (PD) will also strongly rise in the
coming decades (Dorsey et al., 2007). In brains of PD patients,
alpha-synuclein (aSyn) has been found in thread-like fibrils in
Lewy body deposits inside dopaminergic (DAergic) neurons and
also in dystrophic neurites (Spillantini et al., 1997; Del Tredici and
Braak, 2012). Importantly, aSyn pathology does not only affect
DAergic cells but has also been identified in other neuronal cell
populations in the enteric nervous system, olfactory bulb, dorsal
motor nucleus of the vagal and glossopharyngeal nerves and in
other brain stem nuclei explaining the multitude of non-motor
manifestations in PD (Postuma et al., 2012).
ASyn is implicated in familial genetic autosomal-dominant
forms of PD. There exist whole-locus multiplications or point
mutations of aSyn including the A53T and the A30P variant
(Singleton et al., 2013). Whole-locus multiplications seem to lead
Abbreviations: AAV, adeno-associated virus; aSyn, alpha-synuclein; ANOVA,
analysis of variance; BSA, bovine serum albumin; CBA, chicken β-actin; DA,
dopamine; DAergic, dopaminergic; DAPI, 4,6-diamidino-2-phenylindole; DIV, day
in vitro; DMEM, Dulbecco’s modified Eagle’s medium; GAP-43, growth associated
protein 43; GDNF, Glial cell line-derived neurotrophic factor; MDN, mid-
brain dopaminergic neurons; PBS, phosphate-buffered saline; PFA, paraformalde-
hyde; PD, Parkinson’s disease; ROCK, rho kinase; RT, room temperature; SNpc,
Substantia nigra, pars compacta; TH, tyrosine hydroxylase; WT, wildtype.
to an earlier and more severe onset of disease depending on the
gene copy number (Fuchs et al., 2007). The A53T variant has
broadly varying phenotypes and is neuropathologically charac-
terized by DAergic cell loss and a dense burden of aSyn neuritic
pathology including axonal spheroids and rare Lewy bodies with
fibrillar aSyn-immunoreactive aggregates (Duda et al., 2002).
The first patho-anatomical study of an A30P mutation carrier
showed DAergic cell loss in the substantia nigra (SN) as well as
widespread occurrence of aSyn immunopositive Lewy bodies and
Lewy neurites (Seidel et al., 2010). Here, the clinical symptoms
are similar to idiopathic PD (Kruger et al., 2001). Several aSyn
mutations have been transferred into animal models of disease
by the means of genetically engineered transgenic mice or virus-
mediated region-specific protein expression approaches (Low and
Aebischer, 2012).
The initial pathology of PD is likely to be characterized by
axonal degeneration, whereas the loss of DAergic neurons in
the substantia nigra pars compacta (SNpc) follows subsequently
(reviewed in Burke and O’Malley, 2013). In support of this
hypothesis, the extent of terminal loss in the striatum seems to
be much more prominent than the amount of cell loss of nigral
DAergic neurons at the time when first clinical symptoms appear,
suggesting that the striatal DAergic nerve terminals are the pri-
mary target of the degenerative process and that neuronal death in
PD represents a “dying back” pathology (Dauer and Przedborski,
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2003). The axonal insult can be modeled by striatal injection of
6-hydroxydopamine (6-OHDA) in mice and in rats. It causes an
acute retrograde axonal degeneration followed by neuronal loss
in the SN (Deumens et al., 2002). After lesion, the intrinsic regen-
erative potential of DAergic neurons is activated and it leads to a
partial restoration of nigrostriatal tract fibers (Finkelstein et al.,
2000).
In the current study we examined whether targeted expression
of either human aSyn(WT) or the A30P and A53T variants in
nigral DAergic cell populations affect neurite and axonal regen-
eration in lesioned midbrain DAergic neurons (MDN) in vitro
and in 6-OHDA-lesioned DAergic nigral neurons in vivo. We
found that the regenerative response is strongly impaired after
expression of the mutated variants of human aSyn, the A30P vari-
ant being the most compromising one. Interestingly, the amount
of striatal GAP-43-immunopositive regenerating structures was
much more decreased than the density of TH-immunopositive
fibers. Here, the impairment in regenerative growth was asso-
ciated with an activation of the ROCK signaling pathway. The
expression of aSyn(WT) resulted only in minor alterations. These
findings indicate that genetic alterations of aSyn have a strong
impact on the regenerative capacity of DAergic neurons.
MATERIALS AND METHODS
RECOMBINANT VECTOR PRODUCTION
AAV vectors were constructed to express human aSyn(WT), the
A30P or A53T mutation as well as EGFP or only EGFP control.
Viral vectors were prepared as previously described (Shevtsova
et al., 2005). For in vitro applications, the AAV 1/2 or AAV6
serotype was chosen because of its increased transduction effi-
ciency. In case of in vivo injections into the SN, the AAV2 serotype
was selected because of its higher selectivity for neuronal cells.
All AAV consisted of AAV ITRs, human synapsin-1 gene pro-
moter driving expression of aSyn variants/EGFP or EGFP only,
WPRE for enhancedmRNA stability and bovine growth hormone
polyadenylation site (Taschenberger et al., 2012).
IN VITRO DAergic CELL CULTURE AND AAV VECTOR APPLICATION
Primary MDN were prepared according to previously published
protocols (Knoferle et al., 2010). After the mesencephalon floor
of embryonic day 14Wistar rats had been dissected, the meninges
were removed. Dissected tissue pieces were collected in ice-cold
CMF and centrifuged at 1000 rpm for 4min. Thereafter, Trypsin
(750μl, 0.25%, Sigma, Taufkirchen, Germany) was added to the
tissue pellet and after 15min incubation at 37◦C, it was inac-
tivated with 750μl cold FCS. After gentle trituration of tissue
fragments, the cell suspension was centrifuged at 1000 rpm for
4min and resuspended in culture medium.
Cells were then plated at a density of 60,000/well in 96-well
plates or at a density of 400,000/well in 24-well plates (Sarstedt,
Nümbrecht, Germany) on coverslips. Coating was done with
poly-D-lysine and laminin (DIV0). Four hours after plating, cul-
tures were transduced with AAV for EGFP, human aSyn(WT)
or the A30P or A53T aSyn mutations, each in a concentra-
tion of 1 × 108 transducing units per well. Cell cultures were
maintained at 37◦C in a 5% CO2 humified atmosphere in
DMEM-F12 (Invitrogen, Darmstadt, Germany) supplemented
with 2.5mg/ml BSA (35%), 0.9% D-(+)-glucose solution
(45%), 2mM L-glutamine (PAA Laboratories, Pasching, Austria),
5μg/ml insulin, 1:100 N1 medium supplement and 1:100 PSN
antibiotic mixture (Invitrogen, Scotland, UK). On the next day
(DIV1) half of the medium was replaced. On DIV3 cells in 24
well-plates on coverslips were submitted to mechanical transec-
tion using a self-made 2mm broad silicon rubber scratch device
taking care not to damage the poly-D-lysine and laminin coat-
ing (Tönges et al., 2011b). After another three days on DIV6, cells
were processed for immunocytochemistry or for cell viability and
toxicity assays.
IN VITRO IMMUNOCYTOCHEMISTRY, QUANTIFICATION OF NEURONAL
SURVIVAL AND NEURITE REGENERATION
To perform immunocytochemistry, cells plated on coverslips
were fixed in PFA 4% for 10min at room temperature (RT,
22◦C), washed twice with PBS, incubated 30min in 25mM
Glycine in PBS (Applichem, Darmstadt, Germany), permeabi-
lized and blocked with 10% horse serum, 5% BSA, 0.3% Triton,
25mM Glycine in PBS at RT for 1 h. Probes were incubated with
mouse anti-tyrosine hydroxylase 1:500 (Sigma, St. Louis, MO,
USA), rabbit anti-tyrosine hydroxylase 1:1000 (Zytomed Systems,
Berlin, Germany), goat anti-tyrosine hydroxylase 1:500 (abcam,
Cambridge, UK), chicken anti-GFP 1:500 (abcam, Cambridge,
UK),mouse anti-human aSyn LB509 1:1000 (Covance, Princeton,
NJ, USA) overnight at 4◦C in blocking solution. Following three
PBS washes, the respective secondary antibodies [all 1:500, don-
key anti-mouse Alexa Fluor 488 (Life Technologies, Darmstadt,
Germany), donkey anti-goat Cy5, donkey anti-goat Cy3, don-
key anti-rabbit Cy3, goat anti-mouse Cy2, goat anti-mouse Cy3,
goat anti-rabbit Cy3 (Dianova, Hamburg, Germany), goat anti-
mouse Cy5, goat anti-rabbit Cy5, goat anti-chicken Alexa Fluor
488 (Jackson, Suffolk, UK)] were applied for 1 h at RT. Cells
were then nuclear counter-stained with DAPI (4,6-diamidino-
2-phenylindole) (Sigma, St. Louis, MO, USA) and mounted in
Mowiol (Hoechst, Frankfurt, Germany).
In order to quantify DAergic cell survival in culture and neu-
rite regeneration from the scratch site, microscopic pictures were
taken with a Zeiss Axioplan 2 fluorescence microscope equipped
with a CCD camera and AxioVision software (Zeiss, Göttingen,
Germany). For evaluation of DAergic survival within the culture,
pictures of five random visual fields per coverslip at least 200μm
apart from the scratch border were taken with a 20× objective and
numbers of TH-immunopositive neurons were counted. Three
samples of at least two separate experiments were quantified for
each condition. The quantification of TH-immunopositive regen-
erating neurites was done semi-automatically with help of the
NeuronJ axon tracing module of Image J. The length of the 10
longest axons extending from the scratch site of each photomi-
crograph (10× objective) was measured. Three samples of at least
two separate experiments were quantified for each condition.
For the analysis of subcellular aSyn distribution, MDN trans-
duced with the different AAV and immunostained against human
aSyn (LB509, Covance), EGFP and TH were analyzed with
a Leica SP5 confocal microscope (Leica, Biberach, Germany).
Micrographs of TH-positive neurons were taken at 63× mag-
nification with an additional 6× zoom factor. Quantification of
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aSyn fluorescence intensity was performed with Image J (Free Java
software provided by the National Institutes of Health, Bethesda,
Maryland, USA). The fluorescence intensity was measured in a
region of interest (ROI) comprising the largest part of the soma
and in a principal neurite at a distance of 50μm from the soma
over a length of 10μm along the neurite. After subtraction of the
background signal, the integrated density values given by Image J
for each ROI were used as single fluorescence intensity values to
calculate the ratio soma/neurite (n = 20 neurons per condition, 2
independent MDN cultures).
CELL VIABILITY AND TOXICITY ASSAYS
Cell viability and toxicity assays were performed in 96-well
plates after 6 days in culture. To determine cell viability overall
metabolic activity in culture was quantified using the WST1 assay
(Roche, Mannheim, Germany) according to the manufacturer’s
instructions. Briefly, WST1 reagent was added 1:10 to the culture
medium and incubated for 2 h at 37◦C. Absorbance was mea-
sured at 450 against 620-nm reference wavelength using an ELISA
reader (Tecan). To determine cell toxicity, a bioluminescence-
based assay for the release of adenylate kinase (AK) from lesioned
cells was applied according to the manufacturer’s instructions
(ToxiLight®, Lonza, Wakersville, USA). Briefly, the amount of AK
was determined in the culture medium by measuring the AK-
dependent conversion of ADP to ATP and subsequent light emis-
sion by luciferase with a luminometer (Wallac 1450 MicroBeta
Trilux, PerkinElmer, Shelton, USA).
IMMUNOBLOTTING
Primary MDN cultures were plated at a density of 400,000/well
in 24-well plates. Four hours after plating, cultures were trans-
duced with AAV for EGFP, human aSyn(WT), the A30P or
A53T aSyn mutations, each in a concentration of 1 × 108
transducing units per well. After 6 days cells were lysed
with a cell lysis buffer (Thermo Scientific™ Pierce™ RIPA
Buffer, Thermo Fisher Scientific Inc., Waltham, MA, USA)
plus protease inhibitors (“Complete tablets,” Roche, Basel,
Switzerland) and phosphatase inhibitor (“PhosSTOP,” Roche,
Basel, Switzerland). The protein content of all cell samples was
determined using Bradford (Biorad, Munich, Germany) and
equal amounts of protein (20μg) were separated on a sodium
dodecyl sulfate–polyacrylamide gel electrophoresis. Proteins were
then electrotransferred onto a PVDF membrane (Applichem,
Darmstadt, Germany) and blocked with 5%milk in Tris-buffered
saline/Tween-20 (TBS-T) for 1 h. Membranes were then incu-
bated with the primary antibodies anti-human aSyn 1:500
(Invitrogen, Carlsbad, CA, USA), anti-MYPT1 1:500 (SCBT,
Dallas, USA) and anti-β Tubulin 1:10000 (Sigma, St. Louis,
MO, USA) in 5% milk TBS-T and anti-phospho-MYPT1 1:500
(Merck Millipore, Darmstadt, Germany) in 5% BSA TBS-T over
night at 4◦C. This was followed by incubation with correspond-
ing horseradish peroxidase-coupled secondary antibodies (1:1000
for 1 h at room temperature; Dianova, Hamburg, Germany).
ECL-Plus reagent (Amersham, Arlington Heights, IL, USA) was
applied on the membrane and the chemiluminescence was visu-
alized on an AmershamHyperfilm ECL (GEHealthcare, Chalfont
St Giles, GB).
IN VIVO 6-OHDA LESION AND AAV VECTOR APPLICATION
All experimental animal procedures were conducted according
to approved experimental animal licenses issued by the respon-
sible animal welfare authority (Niedersächsisches Landesamt für
Verbraucherschutz und Lebensmittelsicherheit) and controlled by
the local animal welfare committee of the University Medical
Center Göttingen. Animals were housed separately in individually
ventilated cages (IVC, Tecniplast, Hohenpeißenberg, Germany)
and were kept under a 12 h light/12 h dark cycle with free access
to food and water.
Stereotactical injections of 6-OHDA (Sigma) were performed
as described before (Alvarez-Fischer et al., 2008). Briefly, 8–10
weeks-old male C57Bl/6 mice were anesthetized with ketamine
(200mg/kg) and xylazine (10mg/kg). The unilateral right stria-
tum was lesioned by stereotactic injection of 6-OHDA [4μg,
dissolved in a volume of 2μl 0.2% L-ascorbic acid (L-AA, Sigma)
in PBS] or vehicle (2μl, 0.2% L-AA in PBS) at an injection
rate of 0.5μl/min using the following coordinates: AP: +0.04 cm,
ML: −0.18 cm, DV: −0.35 cm. After injection the needle was left
in place for 5min before removal. In case of additional AAV
application, the animals received a stereotaxic injection into the
SN directly after 6-OHDA lesion (AP: −0.29 cm, ML: −0.13 cm,
DV: −0.45 cm) with AAV2 expressing EGFP, human aSyn(WT)
or the A30P or A53T aSyn mutations, each with a total of 1 × 108
transducing units dissolved in 1μl PBS at an injection rate of
0.5μl/min (Suppl. Fig. 1).
IMMUNOHISTOCHEMISTRY AND QUANTIFICATION OF DAergic
NEURONAL LOSS AND AXONAL REGENERATION
Mice were sacrificed by exposure to carbon dioxide 4, 8, or 12
weeks after striatal 6-OHDA lesion and, in the case of the 12
weeks experiment, additional AAV injection into the right SN.
This was followed by a transcardial perfusion with PBS and later
with 4% paraformaldehyde (PFA) in PBS (pH 7.4). Brains were
dissected, post-fixed in PFA overnight at 4◦C, cryoprotected in
30% sucrose in PBS for 24 h at 4◦C, snap frozen, and stored
at −80◦C until sectioning. For each group frontal cryosections
(30μm) through the SN and the striatum were collected and kept
in 0.1% sodium azide/PBS. The further processing employed a
free floating method of immunohistochemistry.
In order to label TH-immunopositive cells in the SNpc, sec-
tions were rinsed in 0.1M TBS (pH 7,4) followed by a treatment
of 10% methanol and of 3% H2O2 in TBS for 5min, then rinsed
again for three times in TBS and blocked with 5% normal goat
serum (NGS) in TBS for 60min. Next, sections were exposed
to a rabbit anti-tyrosine hydroxylase antibody (1:1000; Zytomed,
Berlin, Germany) in 1% NGS for 48 h at 4◦C. After another three
TBS wash steps the sections were exposed to a secondary biotiny-
lated antibody (1:200, Dianova, Hamburg, Germany) in TBS at
RT for 60min followed by rinsing in TBS again and incubation
with the VECTASTAIN ABC Peroxidase (standard Kit, PK-4000,
Biozol, Eching, Germany) for 60min at RT. After another TBS
wash step the sections were treated with 3,3′-diaminobenzidine
(DAB peroxidase substrate Kit, SK-4100, Vector Laboratories,
Germany) for 4min, rinsed again and collected on object slides.
Ultimately, sections were mounted with DPX (Fluka Chemica,
Switzerland).
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In order to evaluate the density of TH-immunopositive stri-
atal fibers, a protocol was applied as published previously (Schulz
et al., 1995). Briefly, slices were incubated in chloroform–ethanol
followed by dehydration, use of anti-tyrosine hydroxylase anti-
body (1:500, Zytomed, Berlin, Germany) and DAB staining (Elite
ABC Kit, Vector Laboratories), nickel intensification, formalin
fixation and dehydration. Entellan® was used to mount the
sections.
The detection of GAP-43-immunopositive staining in TH-
immunopositive fibers in the striatum was performed with
a fluorescence-based labeling method. Here, brain slices were
incubated in 1% H2O2/40% methanol for 15min, then in
1mM EDTA (pH 8) at 80◦C for 30min. Primary anti-GAP-
43 (1:1000, Millipore) and anti-tyrosine hydroxylase antibody
(1:500, Zytomed, Berlin, Germany) were used together with the
respective secondary antibodies (1:2000, Alexa Fluor 488 or Alexa
Fluor 594, Life Technologies, Darmstadt, Germany) to visualize
GAP-43 and TH signal.
Quantification of DAergic cell numbers in the SNpc was
done by counting TH-positive neurons using the Stereo
Investigator software (Stereo Investigator 9.0, MicroBrightField
Inc., Colchester, VT, USA, Zeiss microscope; Dehmer et al.,
2004). Here, every fourth nigral section was evaluated by
overlaying a point grid and counting of TH-immunolabeled
cells with the optical fractionator method (40× objective).
Values represent counts in the unilateral SN of the hemisphere
with striatal 6-OHDA lesion or with striatal vehicle control
injection.
Quantification of striatal TH-density was done as described
earlier (Szegö et al., 2012). Every fourth section was stained and
six sections were analyzed per animal. Six images were taken
of every slice using a 63× objective (Axioskop 2, Zeiss, Jena,
Germany) and the area covered by TH-immunopositive fibers was
measured ten times from the same image following background
subtraction and binarization. Therefore, six sections per animal,
six images per section and 10 measurements per image resulted in
a hierarchically nested design. A generalized linear mixed model
was applied. The identification numbers of animals, sections and
images were set as random factors (R software; R Development
Core Team).
For the quantification of the colocalization of GAP-43 and
TH signals, every fourth section was stained with fluorescent
dyes. Images were taken using a 100× objective (Olympus IX51,
Olympus Germany, Hamburg, Germany). For analysis, the area
of specific staining was measured using ImageJ colocalization
plug-in.
STATISTICAL ANALYSIS
Statistical multiple group comparisons were conducted by
One-Way ANOVA followed by Tukey’s post-hoc test. Striatal
fiber density measurements were performed in a hierarchi-
cally nested design (Szegö et al., 2012). For statistical anal-
yses, Kyplot software version 2.0 (KyensLab Incorporated)
and R software version 2.8.0 (R Development Core Team)
were used. Data are represented as mean ± s.e.m. as indi-
cated. Significances are indicated with ∗p < 0.05; ∗∗p < 0.01;
∗∗∗p < 0.001.
RESULTS
SURVIVAL OF TH-IMMUNOPOSITIVE NEURONS IS REDUCED AFTER
AAV-MEDIATED EXPRESSION OF aSyn
Adeno-associated viral vectors were generated expressing human
aSyn(WT), mutated human aSyn(A30P), or aSyn(A53T) as well
as EGFP under the human synapsin I promoter. A vector which
expressed only EGPF under the human synapsin I promoter was
used as control. All constructs led to a comparable transduction
efficiency as visualized by their EGFP fluorescence. The expres-
sion of human aSyn was similar for all human aSyn-expressing
AAV (Suppl. Fig. 2). In order to evaluate if expression of aSyn
leads to death of DAergic cells in vitro, we transduced MDN
cultures with the respective AAV with a titer of 1 × 108 transduc-
ing units/400,000 cells shortly after plating and quantified TH-
immunopositive cell numbers after 6 days. Here, minor DAergic
cell loss was observed in the aSyn(WT) group (90 ± 4%) if com-
pared to the EGFP control (100± 2%). However, cell survival was
much more reduced in aSyn(A30P) and aSyn(A53T) transduced
cultures (A30P: 57 ± 5%; A53T: 51 ± 2%), suggesting that both
mutated aSyn exerted a higher neurotoxicity to DAergic cells than
the wildtype form (Figure 1). Numbers of TH-negative cells were
unchanged after application of the different AAV as evaluated
on DIV6 (Supplementary Table 1). The evaluation of metabolic
activity and of cytotoxicity-related release of AK inMDN cultures
showed an impairment in all aSyn infected cultures in compari-
son to the EGFP control, however, without exhibiting differences
between the various forms of aSyn (Suppl. Fig. 3).
REGENERATION OF SCRATCH-LESIONED TH-IMMUNOPOSITIVE
NEURITES IS DECREASED AFTER AAV-MEDIATED EXPRESSION OF
MUTATED aSyn
Mutated aSyn is known to contribute to axonal pathology of
DAergic cells. However, it is not known if aSyn or its mutated
forms impair axonal regeneration. After the transduction of
MDN with aSyn expression plasmids encapsuled in AAV vectors
we performed a mechanical neurite scratch lesion and quanti-
fied the length of regenerating neurites after three more days
in culture. We did not observe a significant difference in neu-
rite regeneration in cell cultures, which had been transduced
with wildtype aSyn (87 ± 7%) or the EGFP control (100 ±
5%). In contrast, transduction of the mutated forms of aSyn
both resulted in a strong decrease of neurite regeneration which
was most pronounced for the A30P variant [A30P (65 ± 6%);
A53T (71 ± 7%)] (Figure 2). This implies that the aSyn muta-
tions both interfere with DAergic neurite regenerative behavior
in vitro. Numbers of TH-immunopositive cells at the first 100μm
of the scratch border were comparable to data obtained for the
survival of DAergic neurons in culture as demonstrated before
(Supplementary Table 2).
These effects might be caused by increased local concentra-
tions of aSyn in the neurites that impair neurite outgrowth. To
test this hypothesis, we quantified its fluorescence intensity on
confocal micrographs of MDN transduced with the different AAV
vectors, which had been immunostained against aSyn and TH.
When we calculated the ratio between the fluorescence inten-
sity in the soma and in the neurites of TH-positive neurons,
we found that this ratio was significantly decreased in MDN
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FIGURE 1 | Neurotoxicity of AAV-mediated aSyn expression in MDN
culture. Neurons were transduced 4 h after plating with AAV vectors
expressing EGFP (CTRL) or the aSyn variants (1 × 108 transducing
units/400,000 neurons/well) and were evaluated for cell survival after 6
days in culture. (A) Histogram showing percentages of surviving tyrosine
hydroxylase (TH)-immunopositive neurons in comparison to the EGFP
control. Bars represent means ± s.e.m. ∗p < 0.05, ∗∗∗p < 0.001. (B)
Representative micrographs of MDN cultures labeled against TH (Cy3, red).
Insets show additional DAPI nuclear counter-staining (blue). Scale bar =
400μm, scale bar inset = 200μm.
expressing A30P (14± 3) and A53T (12± 2) but notWT (27± 5)
as compared to EGFP control (27 ± 4) (Figure 3). These data
strongly suggest an accumulation of aSyn in the neurites of TH-
positive neurons transduced with the mutant forms aSyn(A30P)
and aSyn(A53T).
DAergic CELL SURVIVAL IN THE SN AFTER STRIATAL 6-OHDA LESION
IS NOT SIGNIFICANTLY INFLUENCED BY aSyn OVEREXPRESSION
We then employed the 6-OHDA-mouse model of PD to test
our hypothesis that aSyn might interfere with DAergic cell sur-
vival and more importantly with long-term axonal regeneration
in vivo. First, the lesioning effects of unilateral stereotactically
guided striatal 6-OHDA injections in mice on nigral DAergic cell
loss were evaluated. We observed only a moderate loss of DAergic
neurons in the unilateral SNpc, which persisted from 4 to 12
weeks after striatal lesion (Suppl. Fig. 4). The additional ipsi-
lateral nigral injection of AAV vectors with plasmids expressing
human aSyn(WT) or its mutants resulted in a slightly more pro-
nounced loss of DAergic cells 12 weeks after transduction and
FIGURE 2 | Regeneration of TH-immunopositive neurons is decreased
by AAV-mediated expression of mutated aSyn. Neurons were
transduced 4 h after plating with the respective AAV vectors expressing
EGFP (CTRL) or the aSyn forms (1 × 108 transducing units/400,000
neurons/well) and were scratch lesioned after 3 days in culture. Neurite
regeneration was evaluated 3 days after scratch lesion. (A) Histogram
showing the relative outgrowth of TH-immunopositive neurites in
comparison to the EGFP transduced control. Bars represent means ±
s.e.m. n.s. = not significant; ∗p < 0.05. (B) Representative micrographs of
MDN cultures from the site of scratch lesion labeled against TH (Cy3, red).
Dashed line, site of mechanical transection (scratch lesion); arrows, distal
end of regenerating neurites. Scale bar = 100μm. ∗∗∗p < 0.001.
6-OHDA lesion. However, the DAergic cell loss was not signifi-
cant for either aSyn(WT) (7021 ± 330 cells) or its mutants A30P
(6783 ± 580 cells) and A53T (7069 ± 353 cells) in comparison to
the EGFP control (8328 ± 618 cells) (Figure 4). Thus, there was
only modest additional perikaryal neurotoxicity induced by aSyn
overexpression in the SNpc.
MUTATED aSyn IMPAIRS STRIATAL DAergic FIBER REGENERATION
AFTER 6-OHDA LESION
In order to examine an impact of aSyn on axonal regeneration
in vivo we quantified the density of TH-immunopositive fibers
in the striatum after unilateral striatal 6-OHDA lesion and AAV-
mediated ipsilateral nigral expression of aSyn. Establishing this
model system we observed a severe loss of striatal TH-fibers 4
weeks after local 6-OHDA lesion, which recovered after 8 weeks.
After 12 weeks, the fiber density had increased up to 60% of the
unlesioned side (Suppl. Fig. 5). The additional AAV-mediated
expression of aSyn(WT) or its mutants in the ipsilateral SNpc
influenced the relative striatal TH-immunopositive fiber density
compared to the unlesioned side 12 weeks after transduction.
Whereas aSyn(A30P) (47.4 ± 0.8%) significantly reduced the
fiber density if compared to EGFP (54.5 ± 0.8%), aSyn(A53T)
reduced the density of TH fibers only by trend (50.6 ± 1.3%).
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FIGURE 3 | Subcellular distribution of aSyn fluorescence intensity in
MDN transduced with aSyn WT and mutant forms. MDN transduced
with AAV vectors expressing EGFP (CTRL) or the given aSyn forms (1 × 108
transducing units/400,000 neurons/well) were immunostained against aSyn
and TH. The fluorescence intensity of aSyn was quantified in the soma and
in the neurite and the respective ratio was calculated (A). Bars represent
means ± s.e.m. n.s. = not significant; ∗p < 0.05. (B) Representative
confocal micrographs of AAV-transduced (EGFP-positive, green)
dopaminergic (TH-positive, Cy5, blue) neurons stained against aSyn (Cy3,
red). Scale bar = 30μm.
The expression of aSyn(WT) resulted in a small increase of the
TH fiber density (58.8 ± 1.4%) (Figure 5).
The quantification of striatal TH-immunopositive fiber den-
sity after 6-OHDA lesion is only an indirect measure of regen-
erating fibers. Therefore, we decided to examine the presence
of GAP-43 in the lesioned striatum as a more specific marker
for axonal regeneration. The quantification of GAP-43 expres-
sion in DAergic TH-immunopositive fibers of the nigrostriatal
tract showed a reduction of GAP-43 protein levels in the lesioned
striatum as compared to the unlesioned side in control animals,
which had been transduced with an EGFP-expressing plasmid
(70.8 ± 9.2%). In case of AAV-mediated aSyn(WT) expression,
GAP-43 expression amounted to similar levels (75.8 ± 11.5%).
However, the nigral expression of aSyn(A30P) resulted in sig-
nificantly lower GAP-43 levels (18.2 ± 11.7%), which was also
the case, although to a lesser extent, for aSyn(A53T) (30.9 ±
17.9%) (Figure 6). This implies that nigral overexpression of both
aSyn(A30P) and aSyn(A53T) markedly impair the regenerative
response of nigrostriatal tract DAergic neurons. As a putative
mechanism we have identified the involvement of the rho kinase
(ROCK) pathway. After overexpression of both aSyn(A30P) and
aSyn(A53T) in MDN the ROCK downstream target MYPT1 was
clearly phosphorylated indicative of an activation of this pathway.
Interestingly, aSyn(WT) did not activate but rather attenuate
FIGURE 4 | DAergic survival in the SNpc 12 weeks after AAV-mediated
nigral aSyn expression and ipsilateral striatal 6-OHDA lesion. Nigral
neurons were unilaterally transduced with AAV vectors expressing EGFP
(CTRL) or aSyn (WT, A30P and A53T form; each 1 × 108 transducing units)
and were simultaneously lesioned in the ipsilateral striatum with 6-OHDA
(4μg/2μl). (A) Histogram showing numbers of surviving
TH-immunopositive nigral neurons 12 weeks after lesion and AAV injection.
Bars represent means ± s.e.m. (B) Representative micrographs of
substantia nigra mouse brain sections labeled against TH (black).
Scale bar = 500μm.
ROCK downstream signaling being in line with its stabilization
of GAP-43 levels (Figure 7).
DISCUSSION
Axonal degeneration is one of the most striking neuropatholog-
ical characteristics of PD, which contributes to the progression
of clinical symptoms (Burke and O’Malley, 2013). The presence
of excess wildtype or mutated aSyn is known to amplify axonal
damage and may additionally lead to cell death of DAergic neu-
rons (Kirik et al., 2002; Lo Bianco et al., 2002). However, it is
not known to which extent aSyn or its mutations further increase
DAergic cell loss and axonal degeneration in vivo in the presence
of additional stress factors such as 6-OHDA. More importantly,
the impact on the intrinsic regenerative capacity of DAergic fibers
by aSyn is only insufficiently characterized. Therefore, we have
designed appropriate model systems to delineate the role of aSyn
and its mutants in this context. We have found that the A30P and
the A53T mutant forms of aSyn impair neurite and axonal regen-
eration most severely, whereas the impact on perikaryal cell death
is only moderate.
A minor reduction of TH-immunopositive cells after
aSyn(WT) expression was observed in vitro, but this loss
was more pronounced after expression of aSyn(A30P) and
aSyn(A53T). This is in line with previous findings on neuronal
toxicity induced by aSyn(WT) and its mutant forms in primary
mesencephalic cultures (Zhou et al., 2000), SH-SY5Y cells (Junn
and Mouradian, 2002), drosophila neurons (Park et al., 2007),
and more recently patient-derived induced pluripotent stem
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FIGURE 5 | Density of TH-immunopositive striatal fibers 12 weeks after
AAV-mediated nigral aSyn expression and ipsilateral striatal 6-OHDA
lesion. Nigral neurons were unilaterally infected with AAV vectors
expressing EGFP (CTRL) or aSyn (WT, A30P and A53T form; each 1 × 108
transducing units) and were simultaneously lesioned in the ipsilateral
striatum with 6-OHDA (4μg/2μl). (A) Histogram showing the relative
density of TH-immunopositive striatal fibers in comparison to the
unlesioned striatum 12 weeks after lesion and AAV vector injection. Bars
represent means ± s.e.m. n.s. = not significant; ∗p < 0.05, ∗∗∗p < 0.001.
(B) Representative micrographs of the striatum and magnifications after
immunostaining for TH (black). Black squares mark exemplary fields of fiber
analysis. Scale bar = 500μm (overview), 20μm (magnification).
cells (Byers et al., 2011). Overexpression of all variants of aSyn
principally can be neurotoxic for DAergic neurons and this
can depend on the amount of protein (over-)expression and
on the presence of additional stress factors. Importantly, this
data also suggests that in addition to its pathogenic forms also
aSyn(WT) can be toxic depending on the context. Although we
did not observe a relevant cell loss in non-DAergic neurons,
we found both a metabolic impairment and an increased
cytotoxicity-related release of AK after expression of all aSyn
variants. The culture duration may be too short to observe
overt cell death in the non-dopaminergic sub-population, which
FIGURE 6 | Density of GAP-43 protein expression in
TH-immunopositive striatal fibers 12 weeks after AAV-mediated nigral
aSyn expression and unilateral striatal 6-OHDA lesion. Nigral neurons
were unilaterally infected with AAV vectors expressing EGFP (CTRL) or
aSyn (WT, A30P and A53T form; each 1 × 108 transducing units) and were
simultaneously lesioned in the unilateral striatum with 6-OHDA (4μg/2μl).
(A) Histogram showing the relative intensity of GAP-43 in
TH-immunopositive striatal structures in comparison to the unlesioned
striatum 12 weeks after lesion and AAV injection. Bars represent means ±
s.e.m. n.s. = not significant; ∗p < 0.05, ∗∗p < 0.01. (B) Representative
micrographs of the striatum in high resolution after immunostaining for
GAP-43 (green) and TH (red). Scale bar = 20μm.
appears less susceptible to aSyn overexpression than DAergic
neurons.
These in vitro findings have been basically corroborated in
different in vivomodels of viral vector-mediated aSyn overexpres-
sion in the SNpc: AAV-mediated expression of human aSyn(WT)
and aSyn(A53T) in rat nigral neurons resulted in a severe cellu-
lar pathology if the constructs were expressed under the strong
chicken β-actin promoter. Here, loss of dopamine neurons accu-
mulated to up to 80% in both aSyn(WT) and aSyn(A53T)
forms, most likely because both forms of aSyn become toxic if
expressed at higher levels (Kirik et al., 2002). Similar findings
were obtained in a lentiviral-based model of phosphoglycer-
ate kinase promoter-driven overexpression of human aSyn(WT),
aSyn(A30P), and aSyn(A53T) in the SNpc of rats, where DAergic
cell loss of about 30% after 5 months was observed for
aSyn(WT) and aSyn(A30P) and to a lesser extent for aSyn(A53T)
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FIGURE 7 | Activation of ROCK downstream targets by human aSyn
mutants. (A) Quantification of pMYPT/MYPT ratio normalized to CTRL and
tubulin in MDN cultures infected with AAV constructs (each 1 × 108
transducing units) expressing EGFP (CTRL) or variants of aSyn (WT, A30P, or
A53T) in MDN after 6 days in culture. Bars represent means ± s.e.m. n.s. =
not significant; ∗p < 0.05, ∗∗p < 0.01, §p = 0.08. (B) Representative
immunoblots of pMYPT1 and tubulin. (C) Representative immunoblots of
total MYPT1 and tubulin.
(Lo Bianco et al., 2002). In comparison, AAV-mediated nigral
expression of the fibril forming variants of human aSyn(WT)
and aSyn(A30P) both caused progressive DAergic cell loss but
aSyn(WT) displayed the strongest cellular neurotoxicity in a
different study. Here, the progressive cell loss was not found
if prefibrillar and non-aggregating variants aSyn(A56P) and
aSyn(A30P/A56P/A76P) were expressed because these forms
rather induced acute DAergic cell death in the first 4 weeks
(Taschenberger et al., 2012). In view of these data on DAergic sur-
vival, it seems that overexpression of human aSyn(WT) and both
the aSyn(A30P) or aSyn(A53T) mutant forms is harmful and the
extent of toxicity depends on the type of the viral vector and the
promoter used.
In order to study neurotoxic effects of AAV-mediated nigral
aSyn overexpression in the presence of an additional stressor we
have employed the striatal 6-OHDA-lesion paradigm which by
itself caused a DAergic cellular loss of about 30% being stable
from 4 to 12 weeks after lesion. Here, aSyn overexpression caused
a modest additional loss of TH-immunopositive neurons in the
SNpc after 12 weeks, which was comparable for the aSyn WT,
A30P, and A53T forms. Thus, aSyn overexpression appears to be
only a mild neurotoxic factor per se, playing a less prominent role
if a lesioning stressor, e.g., 6-OHDA, is already present. However,
the mere DAergic neuronal survival does not indicate in how
far their axonal projections can be preserved and if the intrinsic
regenerative capacity of DAergic neurons is impaired. Therefore,
we have analyzed the impact of aSyn overexpression on striatal
axonal fiber loss and on the regenerative response both in vitro
and in vivo.
The striatal 6-OHDA lesion itself caused a pronounced axonal
degeneration and led to a decrease of striatal DAergic fiber density
to 30% after 4 weeks, which recovered to 60% after 12 weeks in
our model. Concomitant expression of aSyn(A30P) in the SNpc
caused an additional reduction of TH-immunopositive striatal
fibers 12 weeks after lesion, whereas there was a slight increase
for aSyn(WT) and a non-significant effect for aSyn(A53T). This
indicates that only the A30P variant impairs axonal stability under
6-OHDA stress conditions being in line with the aforementioned
lentiviral study, in which the loss of striatal TH-immunopositive
fibers was also most pronounced for aSyn(A30P) and less for
aSyn(WT) or aSyn(A53T) (Lo Bianco et al., 2002). This obser-
vation was confirmed in aSyn(A30P) transgenic mice, in which
the application of the mitochondrial complex I inhibitor MPTP
strongly reduced the regeneration of DAergic fibers in compari-
son to wildtype animals. Interestingly, the DAergic degeneration
in this model was further increased by chronic L-DOPA treat-
ment, an oxidative stressor (Szegö et al., 2012). However, in this
study the aSyn(A30P) transgenic mouse model was not compared
with other variants of aSyn and the MPTP lesion does rather
evoke a perikaryal lesion in contrast to 6-OHDA which causes a
local lesion to the axonal compartment in the striatum.
In our comparative study, the negative impact of both aSyn
mutants on neurite and axonal regeneration in DAergic cells was
very prominent in comparison to the aSyn(WT) form. In the
regeneration paradigm in vitro, the pathogenic mutant forms of
aSyn reduced neurite regeneration by more than 30%whereas the
wildtype form did not have a significant effect. In another study
in SH-SY5Y cells neurite outgrowth was found to be modulated
by human aSyn(WT) interacting with cytoskeletal proteins such
as spectrin beta non-erythrocyte 1 (SPTBN1). Here, aSyn(WT)
attenuated excess branching caused by SPTBN1 overexpression
(Lee et al., 2012).
We observed an even stronger effect by overexpression of
mutant aSyn on the level of striatal expression of the regen-
eration marker GAP-43. Here, aSyn(A30P) most prominently
reduced GAP-43 expression followed by aSyn(A53T), whereas
aSyn(WT) did not significantly affect GAP-43. To our knowledge,
this is the first description of the effects of aSyn overexpression in
DAergic cells on expression of the regeneration marker GAP-43.
Other studies examining the rat 6-OHDA striatal lesion model
found unchanged levels of striatal GAP-43 protein at 8 weeks
after lesion, whereas there was a strong reduction in GAP-43-
mRNA-immunopositive neurons in the SN which persisted over
time (Iwata et al., 2001). Very interestingly, the neuropathological
examination of a human PD patient who had been continuously
infused with GDNF for 43 weeks into the right putamen revealed
a clear increase in GAP-43 labeling at the ipsilateral side being
associated with an improvement in the clinical UPDRS score and
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an increased 18F-dopa uptake in the ipsilateral posterior putamen
(Love et al., 2005). This underlines the importance of GAP-43 as
marker indicating regeneration in PD. Because striatal GAP-43
was shown to be significantly reduced by DAergic expression of
aSyn(A30P) and aSyn(A53T) in our study, the mutant aSyn forms
seem to be especially detrimental for the regenerative response.
The A30P form has also been shown to provoke cytoskele-
tal alterations such as an increase in levels of filamentous actin
(Chung et al., 2009). In line with this, a cell culture study on
hippocampal neurons with aSyn(A30P) displayed distinct effects
from aSyn(WT) and increased the rate of actin polymerization
with subsequent disruption of the cytoskeleton and induction of
actin-rich foci (Sousa et al., 2009). This is indicative of a decreased
remodeling of axonal terminals and reduced axonal outgrowth
capacity which is similarly seen when there is an increased activ-
ity of the Rho/ROCK signaling pathway (Tönges et al., 2011a).
We have examined the activation of the Rho/ROCK in DAergic
cultures in vitro and could observe a strong activation by both
aSyn mutants which was not the case for aSyn(WT). As pharma-
cological ROCK-inhibition has recently been demonstrated to be
a successful strategy to foster axonal regeneration in toxin-based
models of PD (Tönges et al., 2012), this approach could also be
worthwhile to be evaluated in aSyn-related genetic models of PD.
Our findings indicate that genetic alterations of aSyn have a
clear impact on the regenerative capacity of DAergic neurons
both in vitro and in vivo. In our model systems, aSyn(A53T)
and, more importantly aSyn(A30P), impaired neurite regenera-
tion of MDN in vitro and reduced TH-immunopositive axonal
fiber sprouting of 6-OHDA lesioned DAergic neurons in vivo.
This broadens our understanding of pathogenic effects of aSyn
and its disease-relevant mutants beyond DAergic neurotoxicity.
Accumulating data now suggest an involvement of the ROCK sig-
naling pathway in the pathophysiology of preclinical PD models.
This is a strong argument for the examination of its contri-
bution also to human PD because a variety of ROCK target-
ing strategies are becoming available in the clinics and could
easily applied in a translational approach for this debilitating
disease.
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